ExpansionApr 21, 2026, 08:32 AM
Journey Medical's Emrosi™ Gains 85% US Commercial Access
AI Summary
Journey Medical Corporation announced that its rosacea treatment, Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), has achieved access to approximately 85% of all commercial lives in the United States. This significant milestone follows the company's successful contracting with the third major group purchasing organization (GPO). Journey Medical anticipates that this expanded payer access will drive further growth in total prescription demand, improve patient access, and position Emrosi™ for sustained commercial growth and enhanced profitability.
Key Highlights
- Emrosi™ now has access to approximately 85% of US commercial lives.
- Achieved after contracting with the third major group purchasing organization (GPO).
- Company expects expanded payer access to facilitate further prescription growth.
- Aims for continued health plan formulary adoption throughout 2026 and beyond.